Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience

Che, Wenqiang; Liu, Jie; Fu, Tengyue; Wang, Xiangyu; Lyu, Jun

doi:10.3390/curroncol29110660

Cited by 11 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The natural history of progression from primary cancer to BM varies depending on the site of the primary tumor. According to a study analyzing the incidence and mortality of synchronous BM in the United States, the most common primary tumor site in patients with synchronous BM was the lung (80.3%) [ 21 ]. Likewise, in our study, lung cancer was the most frequently diagnosed at the same time as the primary tumor at 52.8%.…”

Section: Discussionmentioning

confidence: 99%

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

Kim

Lee

et al. 2023

J Pathol Transl Med

View full text Add to dashboard Cite

Background: The metastatic brain tumor is the most common brain tumor. The aim of this study was to demonstrate the clinicopathological and molecular pathologic features of brain metastases (BM).Methods: A total of 269 patients were diagnosed with BM through surgical resection at Seoul St. Mary’s Hospital from January 2010 to March 2020. We reviewed the clinicopathological features and molecular status of primary and metastatic brain tissues using immunohistochemistry and molecular pathology results.Results: Among 269 patients, 139 males and 130 females were included. The median age of primary tumor was 58 years (range, 13 to 87 years) and 86 patients (32.0%) had BM at initial presentation. Median BM free interval was 28.0 months (range, 1 to 286 months). The most frequent primary site was lung 46.5% (125/269), and followed by breast 15.6% (42/269), colorectum 10.0% (27/269). Epidermal growth factor receptor (<i>EGFR</i>) mutation was found in 50.8% (32/63) and 58.0% (40/69) of lung primary and BM, respectively. In both breast primary and breast cancer with BM, luminal B was the most frequent subtype at 37.9% (11/29) and 42.9% (18/42), respectively, followed by human epidermal growth factor receptor 2 with 31.0% (9/29) and 33.3% (14/42). Triple-negative was 20.7% (6/29) and 16.7% (7/42), and luminal A was 10.3% (3/29) and 7.1% (3/42) of breast primary and BM, respectively. In colorectal primary and colorectal cancer with BM, <i>KRAS</i> mutation was found in 76.9% (10/13) and 66.7% (2/3), respectively.Conclusions: We report the clinicopathological and molecular pathologic features of BM that can provide useful information for understanding the pathogenesis of metastasis and for clinical trials based on the tumor’s molecular pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

Kim

Lee

et al. 2023

J Pathol Transl Med

View full text Add to dashboard Cite

show abstract

“…They found that the incidence of Helicobacter pylori -related cancers showed a significant downward trend from 2000 to 2019 and identified the racial/ethnic and geographic disparities in incidence rates. In addition, the demographic disparities in the incidence rates of SBMs [ 95 ], gliomas [ 74 ], and thyroid cancer [ 72 ] have been reported using this approach. The Rate Session in SEER*Sat software can be used to obtain the data when demographic covariables are considered in the exposure indicator and the outcome is a cancer diagnosis.…”

Section: Study Designsmentioning

confidence: 99%

How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology

Che,

Li,

Tsang

et al. 2023

Military Med Res

Self Cite

View full text Add to dashboard Cite

In the United States (US), the Surveillance, Epidemiology, and End Results (SEER) program is the only comprehensive source of population-based information that includes stage of cancer at the time of diagnosis and patient survival data. This program aims to provide a database about cancer incidence and survival for studies of surveillance and the development of analytical and methodological tools in the cancer field. Currently, the SEER program covers approximately half of the total cancer patients in the US. A growing number of clinical studies have applied the SEER database in various aspects. However, the intrinsic features of the SEER database, such as the huge data volume and complexity of data types, have hindered its application. In this review, we provided a systematic overview of the commonly used methodologies and study designs for retrospective epidemiological research in order to illustrate the application of the SEER database. Therefore, the goal of this review is to assist researchers in the selection of appropriate methods and study designs for enhancing the robustness and reliability of clinical studies by mining the SEER database.

show abstract

“…Nonetheless, the opportunity to participate in prospective randomized clinical trials (RCTs) is typically only available to a limited number of patients with breast cancer brain metastasis (BCBM). Design challenges, including heterogeneity of patients, varying definitions of clinical end points, and different methods to assess these end points, have led to excluding most patients with BCBM from RCTs [ 5 , 6 ]. Consequently, while the incidence and survival duration have expanded, clinical research methods for BCBM remain limited [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study

Kim¹,

Park²,

Kim³

et al. 2023

J Med Internet Res

View full text Add to dashboard Cite

Background In recent decades, real-world evidence (RWE) in oncology has rapidly gained traction for its potential to answer clinical questions that cannot be directly addressed by randomized clinical trials. Integrating real-world data (RWD) into clinical research promises to contribute to more sustainable research designs, including extension, augmentation, enrichment, and pragmatic designs. Nevertheless, clinical research using RWD is still limited because of concerns regarding the shortage of best practices for extracting, harmonizing, and analyzing RWD. In particular, pragmatic screening methods to determine whether the content of a data source is sufficient to answer the research questions before conducting the research with RWD have not yet been established. Objective We examined the PAR (Preliminary Attainability Assessment of Real-World Data) framework and assessed its utility in breast cancer brain metastasis (BCBM), which has an unmet medical need for data attainability screening at the preliminary step of observational studies that use RWD. Methods The PAR framework was proposed to assess data attainability from a particular data source during the early research process. The PAR framework has four sequential stages, starting with clinical question clarification: (1) operational definition of variables, (2) data matching (structural/semantic), (3) data screening and extraction, and (4) data attainability diagramming. We identified 5 clinical questions to be used for PAR framework evaluation through interviews and validated them with a survey of breast cancer experts. We used the Samsung Medical Center Breast Cancer Registry, a hospital-based real-time registry implemented in March 2021, leveraging the institution’s anonymized and deidentified clinical data warehouse platform. The number of breast cancer patients in the registry was 45,129; it covered the period from June 1995 to December 2021. The registry consists of 24 base data marts that represent disease-specific breast cancer characteristics and care pathways. The outcomes included screening results of the clinical questions via the PAR framework and a procedural diagram of data attainability for each research question. Results Data attainability was tested for study feasibility according to the PAR framework with 5 clinical questions for BCBM. We obtained data sets that were sufficient to conduct studies with 4 of 5 clinical questions. The research questions stratified into 3 types when we developed data fields for clearly defined research variables. In the first, only 1 question could be answered using direct data variables. In the second, the other 3 questions required surrogate definitions that combined data variables. In the third, the question turned out to be not feasible for conducting further analysis. Conclusions The adoption of the PAR framework was associated with more efficient preliminary clinical research using RWD from BCBM. Furthermore, this framework helped accelerate RWE generation through clinical research by enhancing transparency and reproducibility and lowering the entry barrier for clinical researchers.

show abstract

Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience

Cited by 11 publications

References 54 publications

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology

Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study

Contact Info

Product

Resources

About